Therapeutic Compounds for Friedreich's Ataxia Mitochondrial Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Friedreich's ataxia primarily manage symptoms rather than addressing the underlying mitochondrial dysfunction and frataxin deficiency, lacking effective drug candidates to slow disease progression or improve quality of life.
Innovation Solution
Development of novel therapeutic compounds, including chromanes, quinones, hydroquinones, and hydroxybenzoquinones, which can be administered alone or in combination with other agents to target mitochondrial iron overload, ferroptosis, and lipoxygenase-15 activity, aiming to increase frataxin levels and improve mitochondrial function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current symptom management treatments are used, then patient comfort is improved, but disease progression is not addressed and quality of life deteriorates over time
Solution Approach 1:
The patent applies preliminary action by targeting and correcting the underlying mitochondrial dysfunction and frataxin deficiency before symptoms severely impact quality of life. The therapeutic compounds are designed to restore frataxin expression and mitochondrial iron homeostasis in advance, preventing the progression of neurological deterioration rather than merely managing symptoms after they manifest.
Solution Approach 2:
The patent converts the harmful effect of mitochondrial iron overload into a beneficial therapeutic target. By identifying that iron accumulation in mitochondria causes oxidative stress and neuronal death, the invention uses iron-chelating and iron-regulating compounds to transform this harmful process into a treatable condition, thereby improving both disease progression and quality of life.
2Reliability
If frataxin deficiency is addressed through gene therapy, then mitochondrial function is improved, but treatment complexity and cost increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure and properties of therapeutic compounds to optimize their ability to restore frataxin expression and mitochondrial function. The invention synthesizes and optimizes various chemical compounds (including iron chelators, antioxidants, and frataxin expression modulators) with specific molecular properties that enhance their therapeutic efficacy while maintaining manageable treatment complexity.
Solution Approach 2:
The patent uses intermediary compounds that act as mediators between the goal of restoring frataxin function and the complexity of gene therapy. These chemical compounds serve as accessible, administrable intermediaries that can modulate mitochondrial iron homeostasis and frataxin expression without requiring the complex delivery systems needed for direct gene replacement, thereby reducing treatment complexity while maintaining therapeutic reliability.
3Object-affected harmful factors
If mitochondrial iron overload is reduced, then oxidative stress is decreased, but the mechanism of action is not fully understood
Solution Approach 1:
The patent applies feedback by implementing monitoring and assessment mechanisms to track changes in mitochondrial iron levels, oxidative stress markers, and frataxin expression in response to treatment. By measuring these parameters and using the data to adjust therapy, the invention not only reduces oxidative stress but also gains quantitative understanding of the mechanism of action, transforming the previously unclear pathway into a measurable and controllable process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate potential in increasing frataxin expression, reducing mitochondrial iron, inhibiting ferroptosis, and improving Complex I activity, thereby slowing disease progression and alleviating symptoms of Friedreich's ataxia.
Implementation Method 1
increasing frataxin expression
Implementation Method 2
reducing mitochondrial iron
Implementation Method 3
inhibiting ferroptosis
Implementation Method 4
inhibiting ferroptosis
Implementation Method 5
improving Complex I activity
Data Source
AI summary
The disclosure provides therapeutic compositions (i.e., therapeutic agents) and methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia (e.g., Complex I deficiency), and/or reducing the likelihood or severity of Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions and related reduced versions of said therapeutic compositions, which reduce forms may also be used as therapeutic agents (or prodrugs of the therapeutic agent(s)).